| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.15 | 0.004 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.11 | 0.005 |
| mRNA | BRD-K03536150 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.006 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | -0.1 | 0.006 |
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | -0.088 | 0.006 |
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | 0.087 | 0.007 |
| mRNA | BRD-K27224038 | CTRPv2 | pan-cancer | AAC | -0.2 | 0.007 |
| mRNA | compound 1B | CTRPv2 | pan-cancer | AAC | -0.11 | 0.007 |
| mRNA | NSC632839 | CTRPv2 | pan-cancer | AAC | 0.093 | 0.007 |
| mRNA | ATRA | CTRPv2 | pan-cancer | AAC | -0.096 | 0.007 |